Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Benzinga · 2d ago
Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.